Cybin Inc. Completes Acquisition of Small Pharma Inc.
On October 23, 2023, Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options, and Small Pharma Inc. (TSXV: DMT), a U.K.-based biotechnology company focused on short-duration psychedelic therapies for mental conditions, announced the completion of Cybin's acquisition of all of Small Pharma's issued and outstanding securities pursuant to a court-approved statutory plan of arrangement under the Business Corporations Act (British Columbia).
The combined company resulting from the arrangement is expected to create an international clinical-stage leader in novel psychedelic therapeutics. The arrangement was effected pursuant to the terms of an arrangement agreement dated August 28, 2023, between Cybin and Small Pharma.
Aird & Berlis represented Small Pharma with a team led by Richard Kimel and including Marek Lorenc, Ryan Cohen, Nadia Narain (Corporate/Securities) and Manjit Singh (Tax).